Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 7/20 | 0.77 |
| ▸ | NPC1 | O15118 | 5/20 | 0.77 |
| ▸ | RAB9A | P51151 | 5/20 | 0.77 |
| ▸ | MAPT | P10636 | 5/20 | 0.77 |
| ▸ | POLB | P06746 | 6/20 | 0.72 |
| ▸ | USP2 | O75604 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436677 | 0.81 | TP53 (0.64) | TP53NPC1RAB9AMAPTPOLB | |
| SCHEMBL14800259 | 0.81 | MAPT (0.53) | TP53NPC1RAB9AMAPTPOLB | |
| SCHEMBL14800043 | 0.80 | TP53 (0.57) | TP53NPC1RAB9AMAPTPOLB | |
| SCHEMBL3436199 | 0.77 | POLB (0.61) | TP53NPC1RAB9AMAPTPOLB | |
| SCHEMBL29832786 | 0.77 | TP53 (0.60) | TP53NPC1RAB9AMAPTPOLB | |
| SCHEMBL11723176 | 0.74 | LMNA (0.63) | TP53NPC1RAB9AMAPTPOLB | |
| SCHEMBL11723369 | 0.74 | POLB (0.57) | TP53NPC1RAB9AMAPTPOLB | |
| SCHEMBL11723136 | 0.74 | POLB (0.57) | TP53NPC1RAB9AMAPTPOLB | |
| SCHEMBL14800123 | 0.74 | TP53 (0.62) | TP53NPC1RAB9AMAPTPOLB | |
| SCHEMBL3437820 | 0.74 | TP53 (0.56) | TP53NPC1RAB9AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9200008-B2 | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | CDKN1A, SKP2, CCNI | TP53 86/4885NPC1 3743/4885RAB9A 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.